# Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

> **NCT00791102** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Chicago** · enrollment: 20 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **DRUG:** ASP-1001 nasal spray
- **DRUG:** Placebo for ASP-1001

## Key facts

- **NCT ID:** NCT00791102
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-09
- **Final completion:** 2010-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2013-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00791102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00791102, "Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00791102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*